Clover Health Investments Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed the election of directors, approval of executive compensation, and auditor ratification. Financial results showed strong membership growth and profitability, with ongoing investment in AI-driven care and expansion of the care model. No stockholder questions were raised on voting matters.
-
Q1 2026 saw 51% membership growth, $27M GAAP net income, and 62% revenue growth year-over-year. Gross profit rose 47%, with strong retention, clinical engagement, and scale efficiencies supporting a positive outlook for 2026.
-
AI-driven Medicare Advantage plan reports strong growth, 95%+ retention, and expects GAAP profitability in 2026. Technology platform enables earlier diagnoses and better outcomes, with 70% of members covered by its software. Expansion into SaaS for external providers is underway.
-
Strong 53% membership growth and high retention were achieved through disciplined expansion and technology-driven care. The AI-powered platform enables early disease management, supporting profitability and industry-leading clinical quality. Counterpart Health extends these capabilities to other MA plans, driving further growth and differentiation.
Fiscal Year 2025
-
Achieved full year Adjusted EBITDA profitability in 2025 with 38% membership growth and strong cost control. 2026 guidance targets first full year of GAAP net income profitability, 46% membership growth, and continued operating leverage, supported by a four-star payment year and technology-driven model.
-
Membership grew over 33% year-to-date, driven by AI-powered technology and a focus on PPO Medicare Advantage plans. Clinical outcomes improved with earlier diagnoses and fewer hospitalizations. Financial performance saw gains in adjusted EBITDA and cost management. The company targets 2026 GAAP net income profitability.
-
AI-driven technology is enabling earlier chronic disease management, driving strong membership and revenue growth, and improving clinical outcomes. Operational efficiencies and product expansion support a positive outlook, with expectations for GAAP net income in 2026.
-
Membership and revenue grew sharply year-over-year, but profitability was pressured by a higher mix of new members and elevated utilization. Guidance for 2025 was lowered, but strong retention, technology adoption, and a four-star payment year are expected to drive meaningful profitability in 2026.
-
A tech-enabled Medicare Advantage insurer is achieving rapid membership and revenue growth while sustaining profitability, driven by its AI-powered platform that enables earlier disease detection and better outcomes. Expansion into new markets and third-party SaaS offerings is accelerating, with strong quality scores and a positive financial outlook through 2026.
-
Sustained adjusted EBITDA profitability and 32% year-over-year membership growth were achieved, with insurance revenue up 34% and improved operating leverage. Updated guidance reflects higher BER due to Part D and supplemental benefits, but strong positioning for 2026 is expected.
-
Aveanna Healthcare is executing a strategic transformation focused on scale, partnerships, and modernization, driving strong organic and M&A-fueled growth. Q1 saw 14% revenue growth and a 93% rise in adjusted EBITDA, with 2025 guidance raised and continued expansion in preferred payer agreements and state coverage.
-
Delivered 30% MA membership and 33% revenue growth year-over-year, with Adjusted EBITDA up 279%. Reconfirmed strong 2025 guidance, increased profitability outlook, and highlighted technology-driven care and home services as key growth drivers.
-
AI-powered technology drives earlier diagnosis and better chronic disease management, supporting industry-leading cost ratios and quality scores. Strong financial performance in 2024 sets up for 30% membership and 37% revenue growth in 2025, with SaaS expansion and operational efficiencies fueling future profitability.
-
Material profitability and double Star Rating upgrades were achieved alongside 27% membership growth, driven by a technology-centric care model and the launch of Counterpart for third-party expansion. The platform’s AI-powered insights improved clinical outcomes and quality scores, with future plans focused on growth, further technology enhancements, and expanding partnerships.
Fiscal Year 2024
-
Delivered strong 2024 results with 27% Medicare Advantage member growth, improved profitability, and enhanced Star Ratings. 2025 guidance projects 37% revenue growth, continued investment in technology, and expansion of Home Care and Counterpart Health partnerships.
-
A technology-driven Medicare Advantage provider reported strong financial growth, industry-leading cost ratios, and a 4.0-star rating for 2026. Its AI-powered platform enables proactive care, supporting expansion in core and new markets, with a robust pipeline for SaaS offerings.
-
Achieved strong profitability and raised 2024 guidance, driven by technology-led care management and industry-leading cost ratios. Expanded software offerings to third parties, secured a four-star rating for 2026, and is positioned for growth in core and new markets.
-
Delivered strong Q3 results with significant adjusted EBITDA growth, improved loss ratios, and upgraded Star Ratings for its flagship PPO plan. Positioned for 2025 growth as competitors retreat, with increased investments in quality and technology.
-
Strong 2024 financial results and raised guidance reflect robust growth, industry-leading cost ratios, and successful technology-driven care. Expansion of proprietary AI platform to third parties via Counterpart Health is expected to drive recurring SaaS and services revenue, with multi-year contracts and significant cost savings potential.
-
Focused on Medicare Advantage, the company achieved positive EBITDA and cash flow, improved guidance, and regained a 3.5 Star Rating, supporting richer benefits and growth. Technology-driven care management and new SaaS offerings position it well amid industry headwinds.
-
The company leverages an AI-driven platform to support Medicare Advantage providers, demonstrating improved patient outcomes and lower medical costs. Its new Counterpart Health subsidiary expands this technology to external payers and providers, driving high-margin growth and national scalability.
-
Q2 2024 marked the first positive GAAP net income and strong Adjusted EBITDA, driven by double-digit revenue growth and improved margins. Full-year guidance was raised for revenue and profitability, with a robust balance sheet and continued investment in technology and growth.